Christine Kornhuber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christine Kornhuber has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Vordermark
Department of Radiation Oncology, University Hospital Halle (Saale), Halle (Saale), Germany
4 shared publications - Chris Andre Leucht
Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
1 shared publication - Christian T. Dietzel
Department of Radiation Oncology, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120 Halle (Saale), Germany
1 shared publication - Daniel Medenwald
Department of Radiation Oncology, Health Services Research Group, University Hospital Halle (Saale), Halle (Saale), Germany
1 shared publication - Feras Oskan
Department of Radiation Oncology, University Hospital of Saarland, Homburg, Germany
1 shared publication - Frithjof Lange1 shared publication
Latest Publications
- Open Access
- 22 May 2023
- Published by Springer Nature in Radiation Oncology
- Vol. 18 (1) , 1-8
Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
In stereotactic radiotherapy, dose is prescribed to an isodose surrounding the planning target volume (PTV). However, the desired dose inhomogeneity inside the PTV leaves the specific dose distribution to the gross tumor volume (GTV) unspecified. A simultaneously integrated boost (SIB) to the GTV could solve this shortcoming. In a retrospective planning study with 20 unresected brain metastases, a SIB approach was tested against the classical prescription. For all metastases, the GTV was isotropically enlarged by 3 mm to a PTV. Two plans were generated, one according to the classical 80% concept with 5 times 7 Gy prescribed (on D2%) to the 80% PTV surrounding isodose (with D98%(PTV) ≥ 35 Gy), and the other one following a SIB concept with 5 times 8.5 Gy average GTV dose and with D98%(PTV) ≥ 35 Gy as additional requirement. Plan pairs were compared in terms of homogeneity inside GTV, high dose in PTV rim around GTV, and dose conformity and gradients around PTV using Wilcoxon matched pairs signed rank test. The SIB concept was superior to the classical 80% concept concerning dose homogeneity inside GTV: Heterogeneity index of GTV was in the SIB concept (median 0.0513, range 0.0397–0.0757) significantly (p = 0.001) lower than in the 80% concept (median 0.0894, range 0.0447–0.1872). Dose gradients around PTV were not inferior. The other examined measures were comparable. Our stereotactic SIB concept better defines the dose distribution inside PTV and can be considered for clinical use.
- 22 May 2023
- Published by Springer Nature in Radiation Oncology
- Vol. 18 (1) , 1-8
Open AccessFeasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases
In stereotactic radiotherapy, dose is prescribed to an isodose surrounding the planning target volume (PTV). However, the desired dose inhomogeneity inside the PTV leaves the specific dose distribution to the gross tumor volume (GTV) unspecified. A simultaneously integrated boost (SIB) to the GTV could solve this shortcoming. In a retrospective planning study with 20 unresected brain metastases, a SIB approach was tested against the classical prescription. For all metastases, the GTV was isotropically enlarged by 3 mm to a PTV. Two plans were generated, one according to the classical 80% concept with 5 times 7 Gy prescribed (on D2%) to the 80% PTV surrounding isodose (with D98%(PTV) ≥ 35 Gy), and the other one following a SIB concept with 5 times 8.5 Gy average GTV dose and with D98%(PTV) ≥ 35 Gy as additional requirement. Plan pairs were compared in terms of homogeneity inside GTV, high dose in PTV rim around GTV, and dose conformity and gradients around PTV using Wilcoxon matched pairs signed rank test. The SIB concept was superior to the classical 80% concept concerning dose homogeneity inside GTV: Heterogeneity index of GTV was in the SIB concept (median 0.0513, range 0.0397–0.0757) significantly (p = 0.001) lower than in the 80% concept (median 0.0894, range 0.0447–0.1872). Dose gradients around PTV were not inferior. The other examined measures were comparable. Our stereotactic SIB concept better defines the dose distribution inside PTV and can be considered for clinical use.
- Open Access
- 18 April 2023
- Published by Springer Nature in Radiation Oncology
- Vol. 18 (1) , 1-13
Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting
Background: Small-cell lung cancer (SCLC) is a malignant tumor known for its poor prognosis. In addition to chemotherapy and immunotherapy irradiation plays a big role especially in inoperability. This study evaluated prognostic factors in patients with SCLC, receiving chemotherapy and thoracic irradiation, that may affect overall survival (OS), progression-free survival (PFS) and toxicity. Methods: Patients with limited disease (LD) SCLC (n = 57) and extensive disease (ED) SCLC (n = 69) who received thoracic radiotherapy were analyzed retrospectively. The prognostic factors sex, age, Karnofsky performance status (KPS), tumor-, nodal-stage and timepoint of start of irradiation in relation to the first cycle of chemotherapy were evaluated. Start of irradiation was stratified as early ( $$\le$$ 2 cycles of chemotherapy), late (3 or 4 cycles) and very late ( $$\ge$$ 5 cycles). Results were analyzed by Cox univariate and multivariate as well as logistic regression analysis. Results: The median OS of LD-SCLC patients was 23.7 months in early, and 22.0 months in late start of irradiation. In very late start, median OS was not reached. PFS was 11.8, 15.2 and 47.9 months, respectively. In patients with ED-SCLC OS was 4.3 months in early, 13.0 months in late and 12.2 months in very late start of irradiation. PFS was 6.7, 13.0 and 12.2 months, respectively. Prognosis of patients with LD- or ED-SCLC receiving late or very late start of irradiation was significantly prolonged in OS and PFS compared to an early start (p < 0.05). KPS $$\ge$$ 80 shows a significant increase of OS and PFS in ED-SCLC. Female sex and smaller mean lung dose were associated with lower risk of toxicity. Conclusion: Late or very late start of irradiation is a prognosis-enhancing factor in LD-SCLC and ED-SCLC for OS and PFS. KPS $$\ge$$ 80 increases prognosis of OS and PFS in ED-SCLC as well. Toxicity is less common in female sex and patients with low mean lung dose in LD-SCLC.- 18 April 2023
- Published by Springer Nature in Radiation Oncology
- Vol. 18 (1) , 1-13
Open AccessFactors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting
Background: Small-cell lung cancer (SCLC) is a malignant tumor known for its poor prognosis. In addition to chemotherapy and immunotherapy irradiation plays a big role especially in inoperability. This study evaluated prognostic factors in patients with SCLC, receiving chemotherapy and thoracic irradiation, that may affect overall survival (OS), progression-free survival (PFS) and toxicity. Methods: Patients with limited disease (LD) SCLC (n = 57) and extensive disease (ED) SCLC (n = 69) who received thoracic radiotherapy were analyzed retrospectively. The prognostic factors sex, age, Karnofsky performance status (KPS), tumor-, nodal-stage and timepoint of start of irradiation in relation to the first cycle of chemotherapy were evaluated. Start of irradiation was stratified as early ( $$\le$$ 2 cycles of chemotherapy), late (3 or 4 cycles) and very late ( $$\ge$$ 5 cycles). Results were analyzed by Cox univariate and multivariate as well as logistic regression analysis. Results: The median OS of LD-SCLC patients was 23.7 months in early, and 22.0 months in late start of irradiation. In very late start, median OS was not reached. PFS was 11.8, 15.2 and 47.9 months, respectively. In patients with ED-SCLC OS was 4.3 months in early, 13.0 months in late and 12.2 months in very late start of irradiation. PFS was 6.7, 13.0 and 12.2 months, respectively. Prognosis of patients with LD- or ED-SCLC receiving late or very late start of irradiation was significantly prolonged in OS and PFS compared to an early start (p < 0.05). KPS $$\ge$$ 80 shows a significant increase of OS and PFS in ED-SCLC. Female sex and smaller mean lung dose were associated with lower risk of toxicity. Conclusion: Late or very late start of irradiation is a prognosis-enhancing factor in LD-SCLC and ED-SCLC for OS and PFS. KPS $$\ge$$ 80 increases prognosis of OS and PFS in ED-SCLC as well. Toxicity is less common in female sex and patients with low mean lung dose in LD-SCLC. - Open Access
- 8 September 2017
- Published by Walter de Gruyter GmbH in Current Directions in Biomedical Engineering
- Vol. 3 (2) , 651-654
Gynecological brachytherapy with Elekta microSelectron V3 afterloading system
Objective: For commissioning of source path mo-dels for ring tubes of Nucletron (now Elekta) CT/MR ring applicators, a method was established using a source position simulator (SPS) and a CT scanner. Methods: An acrylic glass support for ring tubes was constructed serving as defined coordinate system. With SPS, 40 positions were set in the ring in steps of 2.5mm from proximal to distal direction. In each position a CT-series was taken with ring plane inside scan plane using a GE Optima 580 scanner (slice width 0.625mm). Evaluation was done in multiplanar recon-struction mode under display settings revealing dummy source shape. With a 3D-cursor dwell position coordinate (center of Ir-192 core) was determined. Measurements were validated by film autoradiography in selected positions. Four rings were investigated: 60° Φ26, 45° Φ26, 60° Φ30, and 45° Φ30 with figures denoting angle between ring plane and stem and ring diameter in mm. Results: The method is feasible to reconstruct source dwell positions with an overall accuracy of ±0.3mm. Detected coordinates are consistent and in excel-lent agreement with those obtained by autoradiography. Comparison with Elekta’s source path models, however, re-vealed mean deviations of up to 3.5mm. Discussion: It is advisable to measure individual source paths and have them added to the data base of the treatment planning system.
- 8 September 2017
- Published by Walter de Gruyter GmbH in Current Directions in Biomedical Engineering
- Vol. 3 (2) , 651-654
Open AccessGynecological brachytherapy with Elekta microSelectron V3 afterloading system
Objective: For commissioning of source path mo-dels for ring tubes of Nucletron (now Elekta) CT/MR ring applicators, a method was established using a source position simulator (SPS) and a CT scanner. Methods: An acrylic glass support for ring tubes was constructed serving as defined coordinate system. With SPS, 40 positions were set in the ring in steps of 2.5mm from proximal to distal direction. In each position a CT-series was taken with ring plane inside scan plane using a GE Optima 580 scanner (slice width 0.625mm). Evaluation was done in multiplanar recon-struction mode under display settings revealing dummy source shape. With a 3D-cursor dwell position coordinate (center of Ir-192 core) was determined. Measurements were validated by film autoradiography in selected positions. Four rings were investigated: 60° Φ26, 45° Φ26, 60° Φ30, and 45° Φ30 with figures denoting angle between ring plane and stem and ring diameter in mm. Results: The method is feasible to reconstruct source dwell positions with an overall accuracy of ±0.3mm. Detected coordinates are consistent and in excel-lent agreement with those obtained by autoradiography. Comparison with Elekta’s source path models, however, re-vealed mean deviations of up to 3.5mm. Discussion: It is advisable to measure individual source paths and have them added to the data base of the treatment planning system.
- Open Access
- 13 September 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 213
Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report
The co-incidence of synchronous intraepithelial neoplasia and early stage invasive lung cancer is not a rare phenomenon. The need for curative treatment and the invasive potential of squamous cell pulmonary carcinoma in situ have been a topic of controversy. Surgical resection still remains the treatment of choice. Varieties of endoscopic techniques such as brachytherapy were developed as an alternative to surgery in selected patients. External beam radiation therapy has been used traditionally in combination with endobronchial brachytherapy in the treatment of roentgenographically occult lung cancer, and can be offered for all patients, but is handicapped, because these tumors are radiographically invisible. We report the first case of a pulmonary carcinoma in situ that was successfully treated with stereotactic body radiation therapy.
- 13 September 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 213
Open AccessSimultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report
The co-incidence of synchronous intraepithelial neoplasia and early stage invasive lung cancer is not a rare phenomenon. The need for curative treatment and the invasive potential of squamous cell pulmonary carcinoma in situ have been a topic of controversy. Surgical resection still remains the treatment of choice. Varieties of endoscopic techniques such as brachytherapy were developed as an alternative to surgery in selected patients. External beam radiation therapy has been used traditionally in combination with endobronchial brachytherapy in the treatment of roentgenographically occult lung cancer, and can be offered for all patients, but is handicapped, because these tumors are radiographically invisible. We report the first case of a pulmonary carcinoma in situ that was successfully treated with stereotactic body radiation therapy.